Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes

Raymond J. Steptoe, … , Janine M. Ritchie, Leonard C. Harrison

*J Clin Invest.* 2003;111(9):1357-1363. [https://doi.org/10.1172/JCI15995](https://doi.org/10.1172/JCI15995).

Bone marrow or hematopoietic stem cell transplantation is a potential treatment for autoimmune disease. The clinical application of this approach is, however, limited by the risks associated with allogeneic transplantation. In contrast, syngeneic transplantation would be safe and have wide clinical application. Because T cell tolerance can be induced by presenting antigen on resting antigen-presenting cells (APCs), we reasoned that hematopoietic stem cells engineered to express autoantigen in resting APCs could be used to prevent autoimmune disease. Proinsulin is a major autoantigen associated with pancreatic β cell destruction in humans with type 1 diabetes (T1D) and in autoimmune NOD mice. Here, we demonstrate that syngeneic transplantation of hematopoietic stem cells encoding proinsulin transgenically targeted to APCs totally prevents the development of spontaneous autoimmune diabetes in NOD mice. This antigen-specific immunotherapeutic strategy could be applied to prevent T1D and other autoimmune diseases in humans.
Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes

Raymond J. Steptoe, Janine M. Ritchie, and Leonard C. Harrison

Autoimmunity and Transplantation Division, The Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Parkville, Victoria, Australia

Bone marrow or hematopoietic stem cell transplantation is a potential treatment for autoimmune disease. The clinical application of this approach is, however, limited by the risks associated with allogeneic transplantation. In contrast, syngeneic transplantation would be safe and have wide clinical application. Because T cell tolerance can be induced by presenting antigen on resting antigen-presenting cells (APCs), we reasoned that hematopoietic stem cells engineered to express autoantigen in resting APCs could be used to prevent autoimmune disease. Proinsulin is a major autoantigen associated with pancreatic β cell destruction in humans with type 1 diabetes (T1D) and in autoimmune NOD mice. Here, we demonstrate that syngeneic transplantation of hematopoietic stem cells encoding proinsulin transgenically targeted to APCs totally prevents the development of spontaneous autoimmune diabetes in NOD mice. This antigen-specific immunotherapeutic strategy could be applied to prevent T1D and other autoimmune diseases in humans.


Introduction

Bone marrow (BM) or hematopoietic stem cell (HSC) transplantation has recently been used to treat clinically severe autoimmune disease (1). In preclinical animal models, effective treatment of spontaneous autoimmune disease requires transplantation of BM or HSCs from disease-resistant strains. To date, this has been achieved by allogeneic BM transplantation (BMT) (2–6) leading to full or mixed chimerism (7, 8). However, the requirement for cytotoxic conditioning of the host and the risk of graft rejection (9) or graft-versus-host disease (10) render this approach unsuitable for widespread clinical application. Transplantation of syngeneic HSCs would avoid these problems and represent a novel, safe, and effective strategy for preventing autoimmune disease.

Antigen presentation by resting antigen-presenting cells (APC), either B cells (11, 12) or dendritic cells (13, 14), is a means of inducing T cell tolerance. Since APCs are derived from HSCs we reasoned that HSCs encoding autoantigen targeted to APCs could be used to induce tolerance and thereby prevent autoimmune disease. Type 1 diabetes (T1D) is an autoimmune disease in which insulin-secreting β cells in the pancreatic islets are destroyed by autoreactive T cells. In humans with T1D and in the NOD mouse model of T1D, several lines of evidence indicate that proinsulin is a key autoantigen that drives β cell destruction (15–18). To test whether syngeneic HSCs encoding autoantigen could prevent autoimmune disease, we transplanted into wild-type NOD mice BM or HSCs from NOD mice in which proinsulin was transgenically targeted to APCs.
orbital venous sinus puncture with a fine glass capillary tube. Blood was collected in Alsever’s anticoagulant, erythrocytes were lysed, and leukocytes were stained and analyzed by flow cytometry. Leukocyte number determined with a hemocytometer was calibrated according to the blood volume obtained. Spleens were pressed through stainless steel mesh, and cells were suspended in RPMI containing 10% FCS. Staining was performed as described previously (19). Briefly, cells were “pre-blocked” by incubation in “blocking mix” (10% vol/vol normal mouse serum and 10% v/v anti-CD16/32 [2.4G2] tissue culture supernatant) at 4 °C for 5 minutes. Cells were incubated with FITC- , PE-, or biotin-conjugated primary antibodies at 4°C for 30 minutes in blocking mix, washed in PBS/1.5%FCS, and incubated with streptavidin-FITC or streptavidin-PE (Caltag Laboratories) as required before a final wash. For cytometry, samples were analyzed on a FACScan (Becton Dickinson, Mountain View, California, USA), and gates were set to include live cells on the basis of forward and side scatter profiles. For analysis, 10^4 forward/side scatter gated cells were collected.

**BM preparation and transfer.** Mice (8–12 weeks old) were euthanized, and femurs and tibiae were collected into cold PBS. BM was flushed with ice-cold PBS containing 2.5% FCS (Trace Scientific, Melbourne, Australia), and erythrocytes were removed by lysis in NH_4Cl/Tris buffer. BM was washed in F2.5 and collected by centrifugation. For T cell depletion, BM was resuspended in RPMI containing 10% FCS. Staining was performed on 25 ng of genomic DNA with target-specific (I-E_k promoter–proinsulin II) primers (forward, tgtgaattctgctctgcg; reverse, tgtcccaagtgaagaagac) and standard-specific (β-actin) primers (forward, ttgatcctttgcttgca; reverse, caactgctacacttgat). Amplicons were detected by SYBR green 1 dye binding (Molecular Probes, Eugene, Oregon, USA). Normalized ratios of target/standard DNA were obtained with Relative Quantitation software (Roche Diagnostics) using PCR efficiency curves generated from DNA dilution series. Genomic DNA prepared from a single NOD-PI mouse was used as the internal standard (calibrator) in each real-time PCR assay. The proportion of NOD-PI-derived cells was determined as the ratio of target (NOD-PI transgene) DNA to standard (β-actin) DNA normalized to the NOD-PI calibrator. The detection limit of the PCR assay was less than 5 pg of target DNA, equivalent to 0.025% NOD-PI-derived cells.

BM engraftment was also quantified by transferring NOD CD45.2 BM (10^7 cells) to irradiated (800 cGy) wild-type NOD (CD45.1) mice, as described above. The proportion of donor CD45.2 cells was analyzed in PBLs and spleen cells by flow cytometry.

**T cell recall response.** Mice were immunized subcutaneously in the flank with 100 µg of ovalbumin (OVA) (Grade V, Sigma-Aldrich, St Louis, Missouri, USA) in complete Freund’s adjuvant (Difco, Detroit, Michigan, USA). Spleens collected 14 days later from euthanized mice were pressed through stainless steel mesh, and cells were suspended in RPMI (GIBCO, Rockville, Maryland) containing 10% FCS (Trace Scientific), 10^{-3} M sodium pyruvate, 10^{-4} M nonessential amino acids (GIBCO), 2 × 10^{-3} M glutamine, and 5 × 10^{-5} M 2-mercaptoethanol (Sigma-Aldrich). Splenocytes were plated
found that mature T cells in NOD BM but not NOD-PI BM were capable of transferring diabetes to immune-deficient NOD.scid mice. Therefore, we tested whether development of diabetes after transfer of whole NOD or NOD-PI BM reflected the diabetogenic potential of transferred mature T cells. Whole BM (40 × 10^6 cells injected intraperitoneally) from NOD mice transferred diabetes to at least 50% of non-irradiated T cell–deficient NOD.scid mice, whereas no mice that received BM from NOD-PI mice developed diabetes. T cells in the BM may have either diabetogenic or regulatory function that could account for the differential ability of NOD and NOD-PI BM T cells to transfer disease to NOD.scid recipients. Therefore, to rule out any contribution of mature T cells T cell–depleted NOD-PI BM than in recipients of NOD BM (3/17 versus 10/15, \( P = 0.003 \)) (Figure 1b). When mice with thymomas at necropsy were removed from the analysis, the

Figure 1

Transplantation of NOD-PI BM inhibits development of diabetes. (a) The incidence of diabetes was significantly reduced in recipients of NOD-PI BM (inverted triangles) as compared with NOD BM (triangles) (\( P = 0.003 \)) or untreated NOD mice (squares) (\( P = 0.001 \)). NOD BM recipients did not differ from the untreated controls. Data are pooled from two experiments in which BM from NOD-PI mice or NOD mice was performed in parallel. (b) The incidence of diabetes was significantly reduced in recipients of T cell–depleted NOD-PI BM (inverted triangles) as compared with T cell–depleted NOD BM (triangles) (\( P = 0.003 \)) or untreated NOD mice (squares) (\( P = 0.036 \)). NOD BM recipients did not differ from untreated controls. Data are pooled from three experiments in which BM from NOD-PI or NOD mice was performed in parallel. Cumulative incidence of diabetes is shown on the y-axis and the age of mice in days on the x-axis.
difference between groups remained statistically significant (2/11 versus 10/15, \(P = 0.012\)).

Cellular immune infiltration of pancreatic islets (insulitis) was assessed 10 weeks after transplantation of T cell–depleted BM (10 \(\times\) 10^6 cells), when mice were approximately 100 days of age. In recipients of T cell–depleted NOD-PI BM, 54% of islets were free of insulitis, and mononuclear cell infiltration was restricted to the islet periphery (peri-insulitis) (Figure 2a). In contrast, in recipients of T cell–depleted NOD BM, only 28% of islets were free of insulitis, and there was extensive infiltration into the islets (Figure 2b). These observations were reflected by a significantly reduced mean insulitis score in recipients of NOD-PI as compared with NOD BM (1.0 ± 0.6 versus 2.1 ± 0.8, \(P = 0.008\)) (Figure 2c). In contrast to insulitis, mononuclear cell infiltration of the submandibular gland (sialitis) was similar in recipients of T cell–depleted NOD-PI or NOD BM and age-matched unmanipulated controls (Figure 2d). This indicates that transfer of NOD-PI BM protects specifically against islet autoimmunity. Similar results were observed after transplanting half the amount of T cell–depleted BM (5 \(\times\) 10^6 cells).

Proinsulin-encoding HSCs and HPCs transfer diabetes prevention. HSCs (lin–/c-kit+/SCA-1+) or HPCs (lin–/c-kit+) were sterile purified from NOD and NOD-PI BM, and small numbers of either were transplanted into irradiated 4-week-old recipients. Hematopoietic reconstitution was rapid, and PBL populations were restored by 8 weeks after BMT (data not shown). Diabetes was totally prevented in recipients of NOD-PI HSCs (0/10) as compared with NOD HSCs (5/9) or untreated controls (8/16) (Figure 3a). The incidence of diabetes was significantly reduced in recipients of NOD-PI HPCs (2/14, \(P = 0.035\)) as compared with NOD HPCs (9/19) or untreated (8/16) controls (Figure 3b).

Diabetes is inhibited in the presence of low levels of NOD-PI BM engraftment. To determine the level of NOD-PI BM

---

**Figure 2**

Transplantation of T cell–depleted NOD-PI BM prevents insulitis but not sialitis. (a) Islets free of inflammatory infiltrate (insulitis) were common in recipients of NOD-PI BM, and infiltration was restricted to the periphery of islets (arrow). (b) Extensively infiltrated islets (indicated by asterisks) were common in recipients of NOD BM. (c) The insulitis score was significantly reduced (\(P = 0.008\)) in recipients of T cell–depleted NOD-PI BM cells (triangles, 1.0 ± 0.6) as compared with NOD BM cells (inverted triangles, 2.1 ± 0.8 [means ± SD]). Data for age-matched NOD mice (squares) and NOD-PI mice (diamonds) are included for comparison. (d) The number of submandibular gland inflammatory foci (sialitis score) did not differ between BMT and untreated mice. Individual mouse scores are pooled from two experiments in which BMT from NOD and NOD-PI mice was performed in parallel (horizontal bar indicates mean).

---

**Figure 3**

Transfer of NOD-PI HSCs or HPCs prevents development of diabetes. (a) Diabetes was prevented in recipients of NOD-PI HSCs (inverted triangles) compared with recipients of NOD HSCs (triangles) (\(P = 0.019\)) or untreated NOD mice (squares) (\(P = 0.029\)). NOD HSC recipients and untreated NOD mice did not differ significantly. (b) The incidence of diabetes was significantly reduced in recipients of NOD-PI HPCs (inverted triangles) compared with recipients of NOD HPCs (triangles) (\(P = 0.035\)) or untreated NOD mice (squares) (\(P = 0.021\)). NOD HPC recipients and untreated NOD mice did not differ significantly. Data are from one (a) or two (b) experiments in which BMT from NOD-PI and NOD mice was performed in parallel.
engraftment required to inhibit diabetes, real-time PCR was used to quantify NOD-PI-derived cells in spleens from mice transplanted with BM, HPCs, or HSCs. After intravenous transfer of 10^5 purified HSCs, a substantial proportion (range, 33–100%) of NOD-PI-derived cells was present in recipient spleens (Table 1), whereas after intraperitoneal transfer of whole or T cell-depleted BM, the proportion (range, 0.1–11.9%) was lower (Table 1). These findings were validated by using congeneric NOD CD45.2 mice as whole BM donors. The level of donor (CD45.2) engraftment in PBL (9.0% ± 5.6%, n = 4) or spleen (8.4% ± 5.5%, n = 6) 12 weeks after intraperitoneal transfer of T cell-depleted BM was similar to that determined by real-time PCR. Although diabetes prevention was 100% at high levels of engraftment, a substantial reduction in diabetes incidence was still observed at low levels of engraftment (Table 1).

Diabetes prevention by NOD-PI bone marrow is not due to impaired immune reconstitution. To exclude the possibility that the protective effect of NOD-PI BMT was the result of impaired immune reconstitution, we first analyzed PBL populations. Ten to fourteen days after BMT, circulating leukocytes remained substantially reduced (Figure 4a). The proportions of CD4+ and CD8+ T lymphocytes and B220+ B lymphocytes were reduced 50–75%, 25%, and 80–85%, respectively, relative to age-matched controls, whereas the proportion of CD11b+ myeloid cells was increased approximately 2.5-fold (data not shown). After 8 and 16 weeks, total PBLs (Figure 4a) and the relative proportion of PBL subsets (Table 2) were normal, indicating similar reconstitution between groups.

We then compared the ability of BMT recipients to mount a T cell–mediated immune response. Normal age-matched NOD mice and recipients of NOD or NOD-PI T cell–depleted BM were immunized with OVA 10 weeks after transplantation, when mice were approximately 100 days of age. Two weeks later, in vitro recall responses to OVA were identical in untreated age-matched NOD mice and either transplant group (Figure 5). Transplantation of T cell–depleted NOD-PI BM was therefore not associated with evidence of impaired immune reconstitution. We could not, however, detect significant T cell–proliferative responses to (pro)insulin T cell epitope peptides aa9–23 or aa24–36 or to human GAD 65 in wild-type NOD mice or in NOD mice 12 weeks after NOD or NOD-PI BMT. Furthermore, the frequency of insulin autoantibodies in recipients of NOD (4/15) and NOD-PI (4/14) BM was no different (data not shown).

**Discussion**

The ability to transfer diabetes in the NOD mouse with BM or HPC (3, 26, 27) demonstrates not only the hematopoietic basis of disease but the potential to prevent autoimmune diabetes by manipulating hematopoiesis-derived cells. Indeed, replacement of the NOD hematopoietic compartment with that from diabetes-resistant strains by BMT prevents development of diabetes (3, 7). To date, however, effective BMT therapy has required generation of full- or mixed-allogeneic chimerism (3, 7, 8, 28) and is limited by toxic conditioning regimens and the risk of graft rejection and/or graft-versus-host disease. Syngeneic transplantation of gene-modified HSCs as described here is a novel approach to antigen-specific immunotherapy that advances the principle of regulating autoimmune disease from within the hematopoietic compartment.

Proinsulin, the prohormonal precursor of insulin, contains T cell epitopes implicated in human (29–31) and mouse (21, 32) T1D. By using NOD mice that express proinsulin transgenically targeted to APCs by an MHC class II promoter (18) as donors, we have been able to show that syngeneic BMT adoptively transfers protection against the development of autoimmune diabetes. Although recipients of BM from NOD-PI mice were substantially protected from diabetes, insulitis was occasionally observed and diabetes developed in a minority. This may be due to the persistence of a small number of radio-resistant pathogenic T cells or to the emergence of T cells after BMT directed at islet antigens other than proinsulin. Complete protection after transfer of highly purified HSCs shows that diabetes prevention depends on the engraftment of multipotent...
hematopoietic cells and not on the inadvertent transfer of immunoregulatory cells in whole or T cell–depleted BM. Because the proinsulin transgene is targeted to MHC class II–expressing cells, we conclude that diabetes prevention is mediated by the APC progeny of transferred HSCs. Our experiments also reveal that diabetes transfer by wild-type NOD HSCs is due to the generation of diabetogenic T cells de novo and not to the transfer of diabetogenic T cells. Clearly, diabetogenic T cells either do not develop or fail to acquire effector function in recipients of NOD-PI HSCs destined to express proinsulin in APCs. These results are a proof of principle that autoantigen-expressing HSCs can be used as a therapeutic tool to prevent autoimmune disease.

It is generally accepted that the context in which antigen presentation occurs controls the nature of T cell immunity (13, 33, 34). Antigen presented by resting APCs induces T cell unresponsiveness (12–14) and inhibits antigen-specific Ab production (13). By transgenically targeting antigen expression, dendritic cells (DCs) have been shown to play a key role in thymic deletion of antigen-specific T cells (35). T cell unresponsiveness in the periphery has also been described after administration of DC-targeted antigen (13, 14). In the present model, further studies are required to determine whether central or peripheral tolerance mechanisms or a combination of both account for diabetes prevention after transfer of PI-encoding HSCs. These would be facilitated if autoantigen-specific T cells could be detected consistently in the NOD mouse; despite reports from a few laboratories (22, 36, 37), this remains a challenge to ourselves and many others (38). In contrast, although insulin autoantibodies can be measured reliably (23), we did not find that they were a marker of diabetes in the present study. Similarly, others (39) have reported that the expression of insulin autoantibodies is transient and not necessarily indicative of diabetes development.

In NOD mice, insulitis is first detected around 3 weeks of age, whereas diabetes is not manifest until about 14 weeks of age. Similarly, TID in humans is preceded by a subclinical phase of islet autoimmunity reflected by the presence of circulating autoantibodies to insulin and other islet antigens (40). The present studies in NOD mice were performed at an age analogous to the early prediabetic phase of human TID. Because preservation of β cell mass and function has been reported after induction of mixed allogeneic chimerism in diabetic NOD mice (7), the present strategy might also be effective at a later age.

Engraftment of donor HSCs was achieved after myeloablative conditioning with irradiation. This establishes proof of principle, but the approach would not be acceptable in asymptomatic humans with preclinical TID. However, because no allogeneic barrier exists, it could be adapted to avoid pre-BMT conditioning. The fact that diabetes was prevented even by low levels of engraftment implies that the low level of engraftment achievable in the absence of myeloablative conditioning (41) may still be effective. By using HSCs derived from transgenic mice, we bypassed the requirement to genetically engineer HSCs ex vivo, which is a major hurdle for HSC therapy. For human application, vectors capable of effectively transducing HSCs for

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>8 weeks after BMT</th>
<th>16 weeks after BMT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NOD BMT (%)</td>
<td>NOD-PI BMT (%)</td>
</tr>
<tr>
<td>CD3*</td>
<td>38.6 ± 7.3</td>
<td>35.6 ± 6.0</td>
</tr>
<tr>
<td>CD4*</td>
<td>29.1 ± 7.1</td>
<td>29.3 ± 3.1</td>
</tr>
<tr>
<td>CD8*</td>
<td>8.8 ± 2.3</td>
<td>8.9 ± 1.3</td>
</tr>
<tr>
<td>B220*</td>
<td>14.3 ± 4.8</td>
<td>9.1 ± 3.2</td>
</tr>
<tr>
<td>CD11b</td>
<td>35.3 ± 12.1</td>
<td>30.6 ± 10.5</td>
</tr>
<tr>
<td>n</td>
<td>19</td>
<td>6</td>
</tr>
</tbody>
</table>

PBL subsets in recipients of T cell–depleted BM from NOD or NOD-PI donors were reconstituted similarly to age-matched NOD controls. Data are means ± SD from two experiments in which BM from NOD and NOD-PI mice was performed in parallel.

![Figure 5](image-url)

**Figure 5**

T cell recall responses to OVA immunization. Mice were immunized subcutaneously with OVA 10 weeks after BMT, and recall responses of splenic T cells were measured 14 days later. T cell proliferation in the presence of OVA was similar in recipients of T cell–depleted NOD (inverted triangles) or NOD-PI (triangles) BM and in age-matched control NOD mice (squares). Data are from individual mice pooled from three separate experiments in which BM from NOD and NOD-PI was performed in parallel.
long-term gene expression after engraftment will be required. Recently, it was shown that gene expression could be effectively targeted to MHC class II–positive APCs in vivo by lentiviral vector transduction of human HSCs (42). We envisage that HSCs could be harvested from peripheral blood of at-risk individuals, genetically modified to encode autoantigen, and reinfused to prevent autoimmune disease.

Acknowledgments

This work was supported by grants from the Juvenile Diabetes Research Foundation, the NIH (DK57228), and the National Health and Medical Research Council of Australia. We thank Lynelle Jones and Runa Daniel for technical assistance, Grant Morahan for NO DCD45.2 congenic mice, Danielle Cooper and Melanie Mager for mouse care, and Catherine O’Shea for secretarial assistance.

34. Frazer, I.H., et al. 2001. Tolerization of diabetes or immunity to a tumor antigen expressed in somatic cells can be determined by systemic proinflamma-
35. Brocker, T., Riedinger, M., and Karjalainen, K. 1997. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstra-

The Journal of Clinical Investigation | May 2003 | Volume 111 | Number 9